. Author manuscript; available in PMC: 2023 Jan 5.

Published in final edited form as: Cancer Prev Res (Phila). 2022 Jul 5;15(7):447–454. doi: 10.1158/1940-6207.CAPR-22-0011

Table 3.

Interaction between aspirin treatment and PRS with risk of colorectal cancer

	Aspirin (cases/person-year)	Placebo (cases/person-year)	HR for aspirin (vs placebo) (95% CI)
Overall	69/27904	74/28083	0.94 (0.68; 1.30)
Low PRS	9/5769	12/5638	0.76 (0.32; 1.81)
Medium PRS	40/16704	44/16893	0.93 (0.60; 1.42)
High PRS	20/5429	18/5551	1.12 (0.59; 2.13)
Interaction (PRS × Aspirin)	-	-	0.97 (0.70; 1.34)

Adjusted for sex, first degree family history of CRC, age at randomisation, smoking (current or former), alcohol (current/no), history of diabetes, BMI. We tested for an interaction between the PRS and aspirin treatment for incident CRC risk in the coxph model using the Wald test. SD=Standard deviation, HR=Hazard ratio, CI=Confidence interval, BMI=Body mass index.